Zoetis and Regeneron Gain Approvals, Positive Market Outlook Ahead
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
Source: Fool
- Zoetis New Drug Approval: Zoetis has received approvals for Lenivia and Portela, its next-gen osteoarthritis pain treatments for dogs and cats, which will help the company maintain a strong market share and improve its financial performance in 2023.
- Market Competition Pressure: Despite competition from products like Apoquel, Zoetis still has significant market potential in the pet health sector, which is expected to drive the company's recovery in 2026.
- Regeneron Drug Expansion: Regeneron has gained approval for a higher-dose version of Eylea and expanded its indications, allowing it to serve a larger patient pool with a more convenient dosing schedule, enhancing its market competitiveness.
- Strong Growth Drivers: Regeneron's Dupixent remains a key growth driver, and the company's pipeline candidates in weight management will further bolster its market performance, with expectations of delivering market-beating returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZTS is 154.20 USD with a low forecast of 130.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 121.930
Low
130.00
Averages
154.20
High
200.00
Current: 121.930
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gold and Silver Aren't the Sole Hot Commodities: Explore Agricultural Stocks.
Focus on Soft Commodities: The article emphasizes the importance of paying attention to soft commodities, which are often overshadowed by the rally in hard commodities like gold and silver.
Market Dynamics: It suggests that the current market dynamics warrant a closer look at soft commodities, as they may present significant investment opportunities.
Continue Reading
Zoetis and Regeneron Gain Approvals, Positive Market Outlook Ahead
- Zoetis New Drug Approval: Zoetis has received approvals for Lenivia and Portela, its next-gen osteoarthritis pain treatments for dogs and cats, which will help the company maintain a strong market share and improve its financial performance in 2023.
- Market Competition Pressure: Despite competition from products like Apoquel, Zoetis still has significant market potential in the pet health sector, which is expected to drive the company's recovery in 2026.
- Regeneron Drug Expansion: Regeneron has gained approval for a higher-dose version of Eylea and expanded its indications, allowing it to serve a larger patient pool with a more convenient dosing schedule, enhancing its market competitiveness.
- Strong Growth Drivers: Regeneron's Dupixent remains a key growth driver, and the company's pipeline candidates in weight management will further bolster its market performance, with expectations of delivering market-beating returns.
Continue Reading